- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07936357
Mindfulness Program for Blood Sugar Control, Heart Rate Variability, Anxiety, and Depression in Type 2 Diabetes
Effect of a Six-Week Mindfulness-Based Intervention on Glycemic Control, Cardiovascular Autonomic Function, Anxiety, and Depression in Adults With Type 2 Diabetes: A Randomized Controlled Trial
The goal of this clinical trial was to learn whether a six-week mindfulness program, added to standard diabetes treatment, improves blood sugar control, heart rate variability (a measure of how the nervous system regulates the heart), anxiety, and depression in adults aged 18 to 60 years with type 2 diabetes. The main questions it aimed to answer were:
- Does the mindfulness program lower glycated hemoglobin (HbA1c), fasting blood glucose, and 2-hour postprandial blood glucose?
- Does it improve heart rate variability, cardiovascular autonomic dysfunction status, and anxiety and depression scores?
Researchers compared participants who received standard therapy plus the mindfulness program with participants who received standard therapy alone.
Participants in the mindfulness group listened to weekly audio-guided practices sent through WhatsApp (mindful eating, breathing exercise, body scan, mindful walking, dealing with unpleasant experiences, and loving-kindness meditation) and were asked to practice daily for six weeks. All participants had blood tests, a 3-minute heart rate variability recording, and the Hospital Anxiety and Depression Scale questionnaire at the start of the study and after six weeks.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This single-center, parallel-group randomized controlled trial with a pretest-posttest design was conducted at the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital, Surakarta, Indonesia, from March to June 2025. Adults with type 2 diabetes receiving antidiabetic treatment were randomly allocated in a 1:1 ratio to standard therapy plus a six-week mindfulness program (intervention) or standard therapy alone (control).
The mindfulness program was adapted from a mindfulness-based stress reduction (MBSR) handbook and consisted of one theme per week: mindful eating, breathing exercise, body scan, staying present (mindful walking), dealing with unpleasant experiences, and loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants were asked to practice daily (approximately 20 minutes per day) and received regular reminders.
Outcomes were assessed at baseline and after six weeks. HbA1c was measured with a point-of-care analyzer (Afinion HbA1c, Abbott); fasting and 2-hour postprandial venous blood glucose were measured with an enzymatic photometric method in the hospital laboratory. Short-term heart rate variability was recorded for 3 minutes with a fingertip photoplethysmographic sensor (SA-3000P, Medicore), and cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values. Anxiety and depression were assessed with the Indonesian version of the Hospital Anxiety and Depression Scale.
The sample size (13 per group, increased to 14 per group to allow for 10% attrition; 28 in total) was calculated with OpenEpi (two-sided alpha 0.05, power 80%). Between-group comparisons used the independent t-test or Mann-Whitney U test, within-group comparisons used the paired t-test or Wilcoxon signed-rank test, and changes in autonomic dysfunction status were analyzed with the McNemar test.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Central Java
-
Surakarta, Central Java, Indonesië, 57126
- Dr. Moewardi General Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adults aged 18-60 years with type 2 diabetes mellitus
- Receiving antidiabetic treatment
- Attending the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital
- Willing to participate and provided written informed consent
Exclusion Criteria:
- Pregnancy or breastfeeding
- Thyroid disorders
- Cardiac arrhythmia
- Use of drugs that may affect heart rate variability (e.g., beta-blockers, antidepressants, antipsychotics, or anxiolytics)
- Coffee consumption within 1 week before the start of the study
- Anemia (hemoglobin <13 g/dL in men or <12 g/dL in women)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Mindfulness plus standard therapy
Participants continued their standard antidiabetic therapy and completed a six-week audio-guided mindfulness program delivered through WhatsApp. |
A six-week mindfulness program adapted from a mindfulness-based stress reduction (MBSR) handbook, with one theme per week: (1) mindful eating, (2) breathing exercise, (3) body scan, (4) staying present - mindful walking, (5) dealing with unpleasant experiences, and (6) loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants practiced daily (approximately 20 minutes per day) and received regular reminders, in addition to standard antidiabetic therapy.
Andere namen:
|
|
Geen tussenkomst: Standard therapy
Participants continued their standard antidiabetic therapy without the mindfulness program. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in glycated hemoglobin (HbA1c)
Tijdsspanne: Baseline and 6 weeks
|
HbA1c (%) measured with a point-of-care analyzer (Afinion HbA1c, Abbott). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in fasting blood glucose
Tijdsspanne: Baseline and 6 weeks
|
Venous blood glucose after an 8-10-hour fast, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in 2-hour postprandial blood glucose
Tijdsspanne: Baseline and 6 weeks
|
Venous blood glucose 2 hours after a meal, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in standard deviation of normal-to-normal intervals (SDNN)
Tijdsspanne: Baseline and 6 weeks
|
Short-term heart rate variability (ms) from a 3-minute recording with a fingertip photoplethysmographic sensor (SA-3000P, Medicore). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Number of participants with cardiovascular autonomic dysfunction
Tijdsspanne: Baseline and 6 weeks
|
Cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values. |
Baseline and 6 weeks
|
|
Change in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) score
Tijdsspanne: Baseline and 6 weeks
|
HADS anxiety subscale, range 0-21; higher scores indicate more severe anxiety symptoms. Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in Hospital Anxiety and Depression Scale - Depression (HADS-D) score
Tijdsspanne: Baseline and 6 weeks
|
HADS depression subscale, range 0-21; higher scores indicate more severe depressive symptoms. Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Farha Naily Fawzia, MD, Universitas Sebelas Maret
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Neuromusculaire aandoeningen
- Metabole ziekten
- Gedragssymptomen
- Ziekten van het perifere zenuwstelsel
- Glucosemetabolismestoornissen
- Suikerziekte
- Diabetes complicaties
- Gedrag
- Voedings- en stofwisselingsziekten
- Angst stoornissen
- Diabetes mellitus, type 2
- Depressie
- Diabetische neuropathieën
Andere studie-ID-nummers
- 2.765/XII/HREC/2024
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data will not be made publicly available to protect participant privacy; de-identified data may be obtained from the principal investigator upon reasonable request.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .